139 related articles for article (PubMed ID: 18342170)
1. Optimal measure of PSA kinetics to identify prostate cancer.
Benecchi L; Pieri AM; Destro Pastizzaro C; Potenzoni M
Urology; 2008 Mar; 71(3):390-4. PubMed ID: 18342170
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
3. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
4. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy.
Bates AT; Pickles T; Paltiel C
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):148-53. PubMed ID: 15850915
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer.
Nowroozi MR; Zeighami S; Ayati M; Jamshidian H; Ranjbaran AR; Moradi A; Afsar F
Urol J; 2009; 6(1):27-30. PubMed ID: 19241338
[TBL] [Abstract][Full Text] [Related]
6. PSA velocity and PSA slope.
Benecchi L
Prostate Cancer Prostatic Dis; 2006; 9(2):169-72. PubMed ID: 16568147
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
8. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
[TBL] [Abstract][Full Text] [Related]
9. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?
Mouraviev V; Broadwater G; Sun L; Mayes JM; Moul JW; Polascik TJ
Urology; 2008 Jun; 71(6):1020-3. PubMed ID: 18267331
[TBL] [Abstract][Full Text] [Related]
10. Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.
Gjengstø P; Paus E; Halvorsen OJ; Eide J; Akslen LA; Wentzel-Larsen T; Hoisaeter PA
J Urol; 2005 Feb; 173(2):425-8. PubMed ID: 15643193
[TBL] [Abstract][Full Text] [Related]
11. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
12. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
[TBL] [Abstract][Full Text] [Related]
13. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
[TBL] [Abstract][Full Text] [Related]
14. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
Shao Q; Song J; Zhou ZJ; Du LD
Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
Bohnen AM; Groeneveld FP; Bosch JL
Eur Urol; 2007 Jun; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
17. [Does plasmatic dilution influence the validity of PSA-tests?].
Rohde D; Mihelcic V
Aktuelle Urol; 2007 Mar; 38(2):137-43. PubMed ID: 17390276
[TBL] [Abstract][Full Text] [Related]
18. Critical analysis of prostate-specific antigen doubling time calculation methodology.
Svatek RS; Shulman M; Choudhary PK; Benaim E
Cancer; 2006 Mar; 106(5):1047-53. PubMed ID: 16456812
[TBL] [Abstract][Full Text] [Related]
19. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
[TBL] [Abstract][Full Text] [Related]
20. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]